News

PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions

VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac EventsSPARTA, N. J.,…

2 years ago

ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late clinical-stage biotechnology company focused on…

2 years ago

ALR Technologies Announces Reincorporation Merger

SINGAPORE, May 20, 2022 (GLOBE NEWSWIRE) -- ALR Technologies Inc. (“ALRT USA”) (OTCQB: ALRT), the diabetes management company, today announces…

2 years ago

Immutep to Present at Investor Conferences

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology…

2 years ago

An organization of women volunteers raises $6 million for Shriners Hospitals for Children – Canada

MONTREAL, May 20, 2022 (GLOBE NEWSWIRE) -- The Daughters of the Nile is an international organization of women dedicated to…

2 years ago

Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) --  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr.…

2 years ago

Kymera Therapeutics Presented Preclinical Data Showcasing Impact of IRAK4 Degrader KT-474 on Immune and Skin Cells at the Society for Investigative Dermatology Annual Meeting

WATERTOWN, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein…

2 years ago

TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

Presentation available for on demand download beginning Tuesday May 24, 2022 at 7:00 AM ETNEW YORK, May 20, 2022 (GLOBE…

2 years ago

BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

- PTR-01 was well-tolerated over a four-month treatment period in RDEB patients - Treatment with PTR-01 led to rapid, consistent,…

2 years ago

Entourage Health Reaffirms First Quarter 2022 Preliminary Record Revenues of $17.4 Million and Announces Financial Results Call to be held on May 31, 2022

Q1 financial filings expected after-market May 30, with management conference call following dayTORONTO, May 20, 2022 (GLOBE NEWSWIRE) -- Entourage…

2 years ago